Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Varubi Generic Name & Formulations
Legal Class
Rx
General Description
Rolapitant 90mg; tabs.
Pharmacological Class
Substance P/NK1 receptor antagonist.
How Supplied
Single dose wallet—1 (4 x 90mg tabs)
Manufacturer
Generic Availability
NO
Varubi Indications
Indications
In combination with other antiemetic agents in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Varubi Dosage and Administration
Adult
Give Varubi before starting each cycle, but at no less than 2 week intervals. Highly emetogenic cisplatin-based chemotherapy: 180mg within 2hrs prior to chemotherapy with dexamethasone 20mg given 30mins prior to chemotherapy and a 5-HT3 receptor antagonist (see drug's full labeling for appropriate dosing) on Day 1, then dexamethasone 8mg twice daily on Days 2–4. Moderately emetogenic chemotherapy and combinations of anthracycline and cyclophosphamide: 180mg within 2hrs prior to chemotherapy with dexamethasone 20mg given 30mins prior to chemotherapy on Day 1 and a 5-HT3 receptor antagonist (see drug's full labeling for appropriate dosing) on Days 1–4.
Children
Not established: see Contraindications.
Varubi Contraindications
Contraindications
Concomitant CYP2D6 substrates with narrow therapeutic index (eg, thioridazine, pimozide): may result in QT prolongation and Torsades de pointes; consider alternatives if use required. Pediatric patients <2yrs of age (due to irreversible impairment of sexual development and fertility).
Varubi Boxed Warnings
Not Applicable
Varubi Warnings/Precautions
Warnings/Precautions
Consider interactions with CYP2D6 substrates before starting treatment. Avoid in severe hepatic impairment; monitor if use cannot be avoided. Advise females of reproductive potential regarding possible infertility. Pregnancy. Nursing mothers.
Varubi Pharmacokinetics
See Literature
Varubi Interactions
Interactions
See Contraindications. Potentiates CYP2D6 substrates (eg, dextromethorphan) and possibly others; see full labeling. Potentiates BCRP substrates (eg, methotrexate, topotecan, irinotecan) and P-gp substrates (eg, digoxin) with narrow therapeutic index; monitor if use cannot be avoided. Use lowest effective dose of rosuvastatin (see drug's full labeling for dosing). Antagonized by strong CYP3A4 inducers (eg, rifampin); avoid. Monitor INR and PT with concomitant warfarin; adjust dose as needed.
Varubi Adverse Reactions
Adverse Reactions
Neutropenia, hiccups, abdominal pain, decreased appetite, dizziness, dyspepsia, UTI, stomatitis, anemia.
Varubi Clinical Trials
See Literature
Varubi Note
Not Applicable
Varubi Patient Counseling
See Literature
